TCAF2 and neoplasm: Exploring the binding site of TCAF2 and TRPM8 would contribute to the development of inhibitors blocking the binding of TCAF2 with TRPM8, as well as to the TPC‐targeting strategy that suppresses tumor hematogenous metastasis through hindering the interaction of TCAF2 and TRPM8 in TPCs.